ࡱ> ]_\q` R <bjbjqPqPh::%@@@@@@@T8D,T(PP"rrrTTTSUUUUUU$hFxyi@2"Ty@@rrOOO$@r@rSOSOO@@OrD O\0(OvOO8@pT>,O$TTTyyXTTT(TTTTTTTTT@@@@@@ Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. q\qge兡N gPlQSShandong Xinhua Pharmaceutical Company Limited(a joint stock company established in the People s Republic of China with limited liability)(Stock Code0719)ANNOUNCEMENT IN RELATION TO A PROPOSED EQUITY ACQUISITION OF A SUBSIDIARY OF THE ACTUAL CONTROLLERThis announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the Listing Rules). In accordance with the requirements and spirit of the State-owned Asset Supervision and Administration Commission of Shandong Province (Shandong SASAC) in relation to the promotion of adjustment and restructuring of enterprises owned by enterprises managed by the provincial government, Hualu Holdings Co., Ltd. (Hualu Holdings ), the actual controller of Shandong Xinhua Pharmaceutical Co., Ltd. (the  Company ) proposes to transfer (the  Proposed Share Transfer ) its state-owned equity, being 80% of the registered capital in its subsidiary, Shandong Zibo Xincat Pharmaceutical Co., Ltd. (Xincat Pharmaceutical). Xincat Pharmaceutical engages mainly in the research and development, production and sales of pharmaceutical preparation. The unaudited figures of Xincat Pharmaceutical for 2011 show that it has total assets of RMB 157.58 million, net assets of RMB 95.22 million, revenues of RMB 253.02 million and a net profit of RMB 25.44 million.With a view to becoming a larger and stronger listed company, the Company proposes to acquire the state-owned equity in Xincat Pharmaceutical (the Intended Acquisition). The Intended Acquisition may or may not proceed. The Proposed Share Transfer is conditional upon the performance by Hualu Holdings of the relevant stipulations and procedures applicable to its disposal of state-owned property rights and the approval of Shandong SASAC. The Intended Acquisition is not legally binding on the Company and there has been no negotiation between the parties in relation to the terms of the Intended Acquisition. Investors and shareholders are advised to exercise caution when dealing in the shares of the Company. Hualu Holdings is the controlling shareholder of Shandong Xinhua Phamaceutical Group Co., Ltd., which has 36.32% equity interest in the Company and as such, Hualu Holdings is a connected person of the Company. If the Intended Acquisition is approved, it will be a connection transaction under the Listing Rules. A valuation will be conducted in relation to the Proposed Share Transfer to determine the consideration (the Consideration) thereof. Upon confirmation of the Consideration by Shandong SASAC, a board meeting of the Company will be held to review and approve the Intended Acquisition (in which interested directors will abstain from voting). Subject to such board approval and, if required, the Intended Acquisition will be submitted for independent shareholders approval in an extraordinary general meeting. Further announcement(s) will be made by the Company in accordance with the Listing Rules and all other applicable requirements.Bp q s t v   v x z . 4 H J R V X r t ׽zzpepzTI=hhO/5CJaJh5CJKHaJ!h5CJKHPJaJnHtHhCJKHaJo(hCJKHaJhCJKHPJaJnHtH/hB*CJOJPJQJ^JaJnHphtHhCJPJaJnHtHhCJaJnHo(tH#hB*CJOJQJ^JaJphjh m U h5CJKH\aJnHtHh6CJ]aJh6CJKH]aJr s u v w  x 2 V X v   sd4gdIqd4WD`gdd4gdyt$d4WD`a$gd$7$8$G$H$a$gdyt$7$8$G$H$a$gd$a$gd$a$gd $7$8$H$a$gd 7$8$H$gd/ <t v    AOerȸwewYwPweBewhIqCJPJaJnHtHhIqCJaJo(hythIq5CJaJ#hhIqCJPJaJnHo(tHhhIqCJaJhh77JCJaJhh!CJaJhhwh ACJaJ"hw5B*CJaJmH phsH hwB*CJaJmH phsH hh#5CJaJhh]5CJaJh5CJaJhh5CJaJh5CJaJo(>N"FT !#-8=CPR]`dir語hIqCJaJo(hIq5CJaJhihIq5CJaJhIqCJaJ hhIqCJPJaJnHtH#hhIqCJPJaJnHo(tH%hythIqB*CJaJmH phsH hhIqCJaJhythIq5CJaJ6rs "%9QRVm.12FGaemyz⤘⬊t⤵t⤊⤬thA hIqCJaJhythIqCJaJhIqCJPJaJnHtHhythIq5CJaJhIqCJaJhIqCJaJo(#hhIqCJPJaJnHo(tH4hythIqB*CJPJaJmH nHo(phsH tHhhIqCJaJ#hythIqCJPJaJnHo(tH-stAB{|{|",,,,$7$8$H$]a$gd$ T 7$8$H$]T^ a$gda$ 7$8$H$]^ a$gda$ 7$8$H$]^ a$gd 7$8$H$gdytd4WD`gdd4gdIqd4WD`gdIq?@BQ-;=>?Mdhiًٚ}hIqCJPJaJnHtHhIqCJPJaJnHo(tH#hhIqCJPJaJnHo(tHhohIq5CJaJhihIqCJaJhIqCJo(hz!hIqCJPJnHtHhhIqCJaJhIq5CJKHaJhIqCJaJo(hIqCJaJ12JKxz{|,,!,",P,,,,,,,,,ŷ~scchCJKHPJaJnHtHhYCJKHaJo(h5CJKHaJh5CJaJhCJKHaJnHtHh5hCJKHaJo(UhCJKHaJhyth5CJKHaJhhR-[CJaJo(#hhIqCJPJaJnHo(tHhhIqCJaJhIqCJaJhIqCJaJo($Y ORDER OF THE BOARD OF DIRECTORSShandong Xinhua Pharmaceutical Company Limited Mr. Zhang DaimingChairman of the Board14 March 2012, Zibo, PRCAs at the date of this announcement, the members of the Board of Directors are:Executive DirectorsMr. Zhang DaimingChairman Mr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Bai HuiliangMr. Kwong Chi Kit, VictorNon-executive Directors:Mr. Ren FulongMr. Xu LieMr. Zhao BinPAGE PAGE,,,"-#-.<.X.z.|...//@/r//Nkd$$If09 UU t644 a$Ifgdgd $7$8$H$a$gd,,,, - ---- -!-"-#-...&.(.8.:.<.H.L.x.|.....///://@/p/r///ϡ鑡ϡwihCJKHaJmH sH 3hB*CJKHOJPJQJ^JaJmH ph!sH hCJKHOJQJ^JaJ6hB*CJKHOJPJQJ^JaJnHo(ph!tH#hB*CJKHaJnHph!tH3hB*CJKHOJPJQJ^JaJnHph!tH+hB*CJKHOJPJQJ^JaJph!'//////////////// &`#$gdgdO/d4WD`gdNkdZ$$If09 UU t644 a$If////////////////////0<<<<<<<< < <źhH1L0JmHnHuUhhsS hsS0JjhsS0JUhbjhbUhhJCJaJhCJKHaJmH sH +hB*CJKHOJPJQJ^JaJph!+hB*CJKHOJPJQJ^JaJph!///<<< < <d4WD`gd &`#$gd 20182P. A!"#$%S nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCBrsuvw"#2./ stuv./HI 1KLMfu000000v000000I00I000000000000000000000000 00000 0 00000 0 0 @0I00@0I00@0I00@0I00@0I0 0I0 0@0@0I00 *(I00 sK0xI0I0I0  $$$'t r,/ < s,// < <  '!!t  ,b$l?xK-}*2>@H 0(  (  P  3 A?"?B S  ?s tFkxď-Gkx-HkxtIkxA3>>BB9*urn:schemas-microsoft-com:office:smarttagsplaceB*urn:schemas-microsoft-com:office:smarttagscountry-region8*urn:schemas-microsoft-com:office:smarttagsCity Xw/t$'(05:jmnty{w/t3/s/IlB-zqxM*VUwCIq m v+ Q`wJV*O/0b0k12(5,=p?77JH1L{LuRsSAUTU [R-[h[_z^$bve(yj {lPryt."v~v1 A}ue HED 4E 84crPaa]mq!lX(rJomowH5hYwD#uy4BDCb,.7|/ILM@ssYssdwwwww@@@ @@@@ @@X@@.@x@UnknownGz Times New Roman5Symbol3& z ArialC .PMingLiUe0}fԚ;[SOSimSun?5 .MingLiU0}fԚ?5 z Courier New 1hsgtg':FR?R?!-!),.:;?]}    & 6"0000 0 000000 =@\]^([{  0 0 00000;[d2QHX ?_z^2sQNb6e-q\NmZSe6Ro gPlQSCgvc:y'`lQJT CARRIECHENGhggSfOh+'0$ 4@ ` l x4չɽͲ´ҩ޹˾ȨʾԹ CARRIECHENGNormal14Microsoft Office Word@\"@*J$@Vv@ZR?՜.+,0 X`t|  my company   !"#$%&'()*+,-./012346789:;<>?@ABCDEFGHIJKMNOPQRSUVWXYZ[^Root Entry FВ`Data 51Table=WordDocumenthSummaryInformation(LDocumentSummaryInformation8TCompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q